

1 **DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT**  
 2 **Disease Control and Environmental Epidemiology Division**  
 3 **RULES AND REGULATIONS PERTAINING TO EPIDEMIC AND COMMUNICABLE**  
 4 **DISEASE CONTROL**  
 5 **6 CCR 1009-1**

6 **Regulation 1. Reportable Diseases**

7 For the purpose of these regulations, the diseases named in lists A and B below are declared to  
 8 be dangerous to the public health and shall be reportable in accordance with the provisions of  
 9 these regulations.

10 The Colorado Board of Health also requires the reporting of any unusual illness, or outbreak, or  
 11 epidemic of illnesses, which may be of public concern whether or not known to be, or suspected  
 12 of being, communicable. Such illnesses include, but are not limited to, Lassa fever, typhus, or  
 13 yellow fever, which have the potential to be brought into Colorado, are readily transmitted, and  
 14 are likely to be fatal. Such outbreaks or epidemics of illnesses include those which may be a risk  
 15 to the public and which may affect large numbers of persons or be outbreaks of a bioterrorist  
 16 agent or of a newly recognized entity; such outbreaks or epidemics shall include but are not  
 17 limited to those related to contaminated medical devices or products or suspected to be related to  
 18 environmental contamination by any infectious agent or toxic product of such an agent.

19 The occurrence of a single case of any unusual disease or manifestation of illness which the  
 20 health care provider determines or suspects may be caused by or related to a bioterrorist agent or  
 21 incident must be reported immediately by telephone to the state or local health department by the  
 22 health care provider and the hospital, emergency department, clinic, health care center, and  
 23 laboratory in which the person is examined, tested, and/or treated. The same immediate reporting  
 24 is required for any unusual cluster of illnesses that may be caused by or related to a bioterrorist  
 25 agent or incident. Bioterrorist agents include, but are not limited to, anthrax, plague, smallpox,  
 26 tularemia, botulism, viral hemorrhagic fever and brucellosis.

27 **List A - Require Report Within 24 Hours (Confirmed or Suspected):**

Animal bites by dogs, cats, bats, skunks, or other wild carnivores	Pertussis
Anthrax	Poliomyelitis
Botulism	Plague
Cholera	Rabies in man (suspected)
Diphtheria	Rubella
Group outbreaks including food poisoning	Severe Acute Respiratory Syndrome (SARS)
Hepatitis A	Smallpox
Measles (rubeola)	Syphilis (1°, 2°, or early latent)
Meningitis or other invasive disease caused by Haemophilus influenzae	Active Tuberculosis disease
Meningitis or other invasive disease caused by Neisseria meningitidis	Typhoid Fever
Meningitis or other invasive disease caused by Neisseria meningitidis	.

28 **List B - Require Report Within 7 Days**

Bites by animals not included in List A	Leprosy
Brucellosis*	Listeriosis

Campylobacteriosis	Lyme Disease
Chancroid	Lymphogranuloma venereum
Chlamydia Trachomatis	Malaria*
Cryptosporidiosis	Meningitis, aseptic*
Cyclospora	Mumps*
Encephalitis*	Psittacosis
Escherichia coli O157:H7** and shiga toxin-producing Escherichia coli	Q Fever*
Giardiasis*	Relapsing Fever*
Gonorrhea, any site	Rocky Mountain Spotted Fever
Hantavirus	Rubella, congenital*
HEALTHCARE-ASSOCIATED INFECTIONS***	Salmonellosis
Hepatitis B*	Shigellosis
Hepatitis C *	Tetanus*
Hepatitis, other viral	Toxic Shock Syndrome
Hemolytic Uremic Syndrome if ≤ 18 yrs	Transmissible spongiform encephalopathy*
Influenza-associated hospitalization	Trichinosis*
Influenza-associated death if < 18 yrs	Tularemia*
Kawasaki Syndrome	Varicella*
Legionellosis*	

- 1 \* Reports shall be based on the physician's diagnosis, whether or not supporting laboratory data are available.
- 2 \*\* This includes any shiga-toxin test or O157 antigen test that is positive, even if no culture is performed. If the laboratory does not have
- 3 the capacity to perform H (flagellar) antigen tests, then Escherichia coli 0157 should be reported.
- 4 \*\*\* CONDITION REPORTABLE ONLY BY FACILITIES LOCATED IN THE DENVER METROPOLITAN AREA (ADAMS, ARAPAHOE, DENVER,
- 5 DOUGLAS, AND JEFFERSON COUNTIES) THAT ARE VOLUNTARILY PARTICIPATING IN APPLIED PUBLIC HEALTH PROJECTS. APPENDIX A INCLUDES A
- 6 DEFINITION OF HEALTHCARE-ASSOCIATED INFECTIONS, A LIST OF INCLUDED INFECTIONS, AND A LIST OF INCLUDED HEALTH FACILITY TYPES.

7 **Manner of Reporting**

8 All cases are to be reported with patient's name, date of birth, sex, race, ethnicity, and address

9 (including city and county) and name and address of responsible physician; and such other

10 information as is needed to locate the patient for follow up. For animal bites by dogs, cats, bats,

11 skunks, and other wild carnivores, the name and locating information of the owner of the biting

12 animal shall be reported, if known, by the health care provider. For all other animal bites, only

13 the number of cases seen need be reported. FOR HEALTHCARE-ASSOCIATED INFECTIONS, EXCEPT

14 AS PROVIDED IN C.R.S. § 25-3-6, FACILITIES CHOOSING TO VOLUNTARILY PARTICIPATE IN APPLIED

15 PUBLIC HEALTH PROJECTS ON A PROJECT BY PROJECT BASIS SHALL MAKE MEDICAL RECORDS

16 AVAILABLE FOR REVIEW BY THE DEPARTMENT UPON REQUEST WITHIN A REASONABLE TIME FRAME.

17 All cases of diseases in list A, and all cases of diseases marked with a single asterisk (\*) in list B

18 shall be reported based on the attending physician's diagnosis, whether or not supporting

19 laboratory data are available. All other diseases in list B shall be reported only when the

20 physician's diagnosis is supported by laboratory confirmation.

21 Reports on hospitalized patients may be made part of a report by the hospital as a whole.

22 The Department shall develop systems and forms for reporting for physicians, other health care

23 providers and hospitals. When hospitals and laboratories transmit disease reports electronically

1 using systems and protocols developed by the department that ensure protection of  
 2 confidentiality, such reporting is acceptable and is considered good faith reporting.

3 **Regulation 2. Reporting by Individuals**

4 Cases of diseases listed in Regulation 1 shall be reported by the attending physician and by other  
 5 persons either treating or having knowledge of a reportable disease, including, but not limited to  
 6 coroners, persons in charge of hospitals or other institutions licensed by the Colorado  
 7 Department of Public Health and Environment, (or their designees), persons in charge of schools  
 8 (including school nursing staff) and licensed day care centers.

9 **Regulation 3. Laboratory Reporting**

10 Cases of diseases listed in Regulation 1 shall also be reported with the information required in  
 11 Regulation 1 by laboratories whether or not associated with a hospital, and by out of state  
 12 laboratories that maintain an office or collection facility in Colorado or arrange for collection of  
 13 specimens in Colorado. For test results required to be reported by laboratories in Regulation 3  
 14 that are not listed in Regulation 1, unless the information or timeframe for reporting is otherwise  
 15 specified, the laboratory shall report within 7 days the patient's name, date of birth, sex, race,  
 16 ethnicity, and address (including city and county); the name and address of responsible  
 17 physician; and such other information as is needed to locate the patient for follow-up. Results  
 18 must be reported by the laboratory, which performs the test, but an in-state laboratory which  
 19 sends specimens to an out-of-state laboratory referral laboratory is also responsible for reporting  
 20 results. A case shall be reported by a laboratory when a result diagnostic of or highly correlated  
 21 with clinical illness is found for any of the following organisms or diseases. Test results  
 22 indicating acute infection or chronic infectiousness for any of the following should be reported.  
 23 Laboratory assays which demonstrate only immunity should not be reported (for example, a  
 24 single elevated rubella antibody titer obtained during routine prenatal screening should not be  
 25 reported).

Bacillus anthracis	Neisseria gonorrhoeae
Bordetella pertussis	Plasmodium species
Borrelia burgdorferi	Poliomyelitis
Brucella species	Q Fever
Campylobacter species	Rabies
Chlamydia psittaci	Relapsing Fever (Borrelia species)
Chlamydia trachomatis	Rocky Mountain Spotted Fever
Clostridium botulinum	Rubella (acute infection)
Corynebacterium diphtheriae	Severe Acute Respiratory Syndrome (SARS)
Cryptosporidium species	St. Louis encephalitis
Cyclospora	Salmonella species, including typhi
Escherichia coli 0157:H7** and shiga toxin-producing Escherichia coli	Shigella species
Francisella tularensis	Smallpox
Giardia lamblia	Treponema pallidum
Haemophilus ducreyi	Vancomycin resistant Staphylococcus aureus, any site
Hantavirus	Varicella
Legionella species	Vibrio cholerae
Listeria monocytogenes	Vibrios, non-cholera

Measles (acute infection)	Western equine encephalitis
Mumps	West Nile virus (acute infection)
Mycobacterium tuberculosis, including antimicrobial sensitivity test results and positive AFB sputum smears.	Yersinia pestis
.	Yersinia, non-pestis +

1 In addition to the above list, a laboratory shall report a case when any of the following specific  
2 laboratory results are found:

- 3 Group A streptococci - positive culture from a normally sterile site\*
- 4 Group B streptococci - positive culture from a normally sterile site\*
- 5 Methicillin resistant Staphylococcus aureus (MRSA) - positive culture from a normally sterile  
6 site (30 day timeframe for reporting)\*
- 7 Clostridium difficile - any positive test (30 day timeframe for reporting)\*
- 8 Haemophilus influenzae - positive culture from a normally sterile site
- 9 Hepatitis A - positive IgM anti-HAV
- 10 Hepatitis B - positive HBsAg, IgM anti-HBc, HBeAg, or HBV DNA
- 11 Hepatitis C - positive serum antibody titer, including signal to cut-off ratio or more specific  
12 positive tests
- 13 Neisseria meningitidis - positive culture from a normally sterile site
- 14 Streptococcus pneumoniae - positive culture from a normally sterile site

15 • Condition reportable only in the Denver Metropolitan Area (Adams, Arapahoe, Denver, Douglas, and Jefferson Counties.)

16 • Condition reportable only in the 7 county Denver Metropolitan Area (Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas, and  
17 Jefferson Counties.)

18 \*\* This includes any shiga-toxin test or O157 antigen test that is positive, even if no culture is performed. If the laboratory does not have the  
19 capacity to perform H (flagellar) antigen tests, then Escherichia coli 0157 should be reported.

20 Reference laboratories that receive specimens from other laboratories shall report results  
21 separately for each submitting facility. ~~The state or local health department may have access to  
22 pertinent, relevant medical and epidemiologic information about the individuals from whom  
23 cultures were collected in order to investigate drug-resistant communicable diseases and to  
24 develop and evaluate strategies to control the spread of these diseases.~~

25 **Regulation 4 Treatment and Control of Tuberculosis**

26 The emergence of multiple drug-resistant tuberculosis in this country and state dictates a  
27 coherent and consistent strategy in order to protect the public health from this grave threat. The  
28 underlying principles of disease control expressed in the following rules are as follows: use of  
29 the most rapid and modern diagnostic methods by laboratories, rapid reporting, full patient  
30 compliance with medical treatment, and prevention of spread of tuberculosis in health care  
31 settings. The tuberculosis statute (C.R.S. 25-4-501 et seq) covers subject matters not included in  
32 these regulations.

- 33 A. All confirmed or suspected cases of active tuberculosis disease, regardless of whether  
34 confirmed by laboratory tests, shall be reported to the state or local health department or  
35 health agency within 24 hours by physicians, health care providers, hospitals, other  
36 similar private or public institutions, or any other person providing treatment to the  
37 confirmed or suspected case. The reports shall include the following information: the  
38 patient's name, date of birth, sex, race, ethnicity, address (including city and county),  
39 name and address of the reporting physician or agency; and such other information as is  
40 needed to locate the patient for follow-up. If reported by a physician, the physician shall

1 also give the evidence upon which the diagnosis of tuberculosis was made, the part of the  
2 body affected, and the stage of disease.

3 B. Physicians, health care providers, and health care facilities shall report within 7 days the  
4 following ppd skin test result if it occurs in a health care worker, correctional facility  
5 worker, or detention facility worker: a positive ppd (defined as = 5 mm induration) if the  
6 worker has had prolonged or frequent face-to-face contact with an infectious tuberculosis  
7 case.

8 C. Laboratories shall report within 24 hours any result diagnostic of or highly correlated  
9 with active tuberculosis disease, including cultures positive for Mycobacterium  
10 tuberculosis and sputum smears positive for acid fast bacilli, and shall report the results  
11 of tests for antimicrobial susceptibility performed on positive cultures for tuberculosis.

12 D. Results must be reported by the laboratory which performs the test, but an in-state  
13 laboratory which sends specimens to an out-of-state referral laboratory is also responsible  
14 for reporting the results.

15 E. A laboratory may fulfill its requirement to report (in parts C and D of this regulation) by  
16 submitting a sputum specimen from the patient to either the State Public Health  
17 Laboratory, or for facilities located in Boulder, Broomfield, Denver, Adams, Douglas,  
18 Arapahoe, and Jefferson counties, to the Denver Public Health laboratory. The reporting  
19 requirement is not fulfilled if the laboratory submits an isolate from a culture to either of  
20 the public health laboratories or if the laboratory delays sending the sputum specimen for  
21 more than 2 days after collection of the specimen.

22 F. When a laboratory performs a culture that is positive for Mycobacterium tuberculosis, the  
23 laboratory shall store the isolate until it receives notification from the state or local health  
24 department that the patient has completed a full and appropriate course of treatment for  
25 active tuberculosis disease. In lieu of such storage, the laboratory may fulfill this  
26 requirement by submitting the isolate to either the state public health laboratory, or for  
27 facilities located in Boulder, Broomfield, Denver, Adams, Douglas, Arapahoe, and  
28 Jefferson counties, to the Denver Public Health Laboratory.

29 G. The State or local health department is authorized to perform evaluations of the  
30 timeliness of laboratory diagnostic processes. The data collected in an evaluation may  
31 include the mean, median, and range for the following indices: the length of time from  
32 specimen collection to isolation; the length of time from isolation of an organism to  
33 identification of the organism as Mycobacterium tuberculosis; and the length of time  
34 from isolation until susceptibility test results are finalized. The state or local health  
35 department shall provide the laboratory and hospital the results of its evaluation,  
36 including comparison of the laboratory indices to norms for other similar laboratories.

37 H. The Board of Health determines that to prevent the emergence of multiple drug- resistant  
38 tuberculosis, it is necessary and appropriate and good medical practice that persons with  
39 active tuberculosis disease receive directly observed treatment for their disease. All  
40 medical providers and health care organizations are required to provide directly observed  
41 therapy for patients with active tuberculosis disease for the full course of therapy, unless  
42 a variance for a particular patient from this requirement is approved by the tuberculosis  
43 control program of the State Department of Public Health and Environment or Denver  
44 Public Health. Directly observed therapy is not required for patients with extrapulmonary  
45 tuberculosis disease provided that the presence of pulmonary tuberculosis has been

1 investigated and excluded. In applicable situations, a variance shall be granted in  
2 accordance with C.R.S. 25-4-506(3).

3 Medical providers and health care organizations shall report to the state or local health  
4 department within seven days the name of any patient on directly observed therapy who has  
5 missed one dose. When requested by medical providers and health care organizations, the state  
6 or local health department shall provide directly observed treatment to outpatients with active  
7 tuberculosis disease and this shall fulfill the requirement for the medical providers and health  
8 care organizations.

9 I. All hospitals and health care facilities providing in-patient treatment to persons with  
10 active tuberculosis disease shall notify the state or local health department immediately  
11 after plans are made to discharge the patient from the facility. The notification is intended  
12 to discuss the treatment plan for the patient and to assure adequate follow-up and  
13 coordination among providers so that the standard of directly observed treatment is met.

14 J. All licensed hospitals and nursing home facilities shall maintain a register of the  
15 tuberculosis skin test results of health care workers in their facility, including physicians  
16 and physician extenders who are not employees of the facility but provide care to or have  
17 face-to-face contact with patients in the facility. The facility shall maintain such  
18 tuberculosis skin test results as confidential medical information. Pursuant to C.R.S. 25-  
19 4-508, authorized personnel of the department of public health and environment may  
20 inspect and have access to such register in the course of an investigation intended to  
21 identify sources and contacts of a case of active tuberculosis disease and to control  
22 tuberculosis.

23 K.(1) With respect to tuberculosis treatment and control, the chief medical health officer of a  
24 local health agency must be a physician licensed to practice medicine in the State of  
25 Colorado. The chief medical health officer of a local health agency may design a  
26 program, consistent with good medical practice, of required screening for latent TB  
27 infection. The objective of the program must be to target persons who are at high risk of  
28 such infection based on recent local, state, national, or international epidemiologic data  
29 concerning the incidence of and risk factors for tuberculosis. The programs shall be  
30 limited to screening persons who participate in activities or who work in occupations and  
31 job categories that have a reasonably large proportion of persons at increased risk of  
32 tuberculosis. The programs should be designed so that the initial step in screening is the  
33 determination of whether a person has recognized risk factors for tuberculosis and if yes,  
34 then said person should undergo a TB skin test and clinical evaluation. If free of signs  
35 and symptoms of tuberculosis, subsequent testing would be dependent on the results of  
36 the TB skin test.

37 (2) The chief medical health officer of a local health agency, with the prior approval  
38 of the local board of health and pursuant to the requirements of subparagraph 3 of  
39 this paragraph K may require screening be performed for a particular group or  
40 population that has been identified as high risk based on the criteria set forth in  
41 this paragraph K, but each individual shall be informed of his or her right to be  
42 exempt from the screening because of medical or religious reasons. The local  
43 health agency should provide at least 30 days notice to potentially affected  
44 persons, groups, and businesses prior to consideration of the proposed program by  
45 the local board of health.

- 1 (3) Except as provided in subparagraph 6 of this paragraph K, no program approved  
2 by a local board of health shall be implemented without the approval of the State  
3 Board of Health. Within 30 days of a program having been approved by a local  
4 board of health, the local health agency shall submit a copy of the proposed  
5 program to the State Board of Health. When considering a proposed local health  
6 agency program, the State Board of Health shall provide notice to all parties on its  
7 mailing list at least 20 days prior to the hearing.
- 8 (4) If an individual has signs and symptoms compatible with tuberculosis in the  
9 infectious stages, the chief medical health officer may require examination  
10 pursuant to 25-4-506, C.R.S. The screening may be performed by an institution,  
11 organization, or agency acting at the direction of the local health agency. The  
12 results of screening shall be given in writing to the person screened. Any person  
13 who is found to have latent TB infection without evidence of active disease shall  
14 be counseled and offered appropriate treatment by the agency performing the  
15 screening, but the person is not required to take such treatment.
- 16 (5) Locally required screening programs shall be evaluated and reviewed by the local  
17 board of health every three years.
- 18 (6) Nothing in this rule shall prohibit the State Health Department or the local health  
19 agency from developing voluntary screening programs, from investigating and  
20 screening contacts of suspected or confirmed cases of tuberculosis in a contagious  
21 form, or from responding to potential outbreaks of tuberculosis in a community.

22 **Regulation 5. Investigations to Confirm the Diagnosis, Treatment, and Causes of Epidemic**  
23 **and Communicable Diseases and to Determine Appropriate Methods of Epidemic**  
24 **and Communicable Disease Control**

25 Investigations may be conducted to confirm the diagnosis, treatment, and causes of reportable  
26 conditions and shall be considered official duties of the health department or health agency. Such  
27 investigations may include, but are not limited to:

- 28 (a) review of pertinent, relevant medical records by authorized personnel, if  
29 necessary to confirm the diagnosis; to investigate causes; to identify other cases  
30 related to the outbreak or the reported communicable disease in a region,  
31 community, or workplace; to determine if a patient with a reportable disease has  
32 received adequate treatment to render him/her non-infectious or a person exposed  
33 to a case has received prophylaxis, if appropriate. Such review of records may  
34 occur without patient consent and shall be conducted at reasonable times and with  
35 such notice as is reasonable under the circumstances;
- 36 (b) performing follow-up interview(s) with the case or persons knowledgeable about  
37 the case to collect pertinent and relevant information about the cause(s) of or risk  
38 factors for the reportable condition;
- 39 (c) medical examination and testing of persons with the explicit consent of such  
40 persons;
- 41 (d) obtaining from public or private businesses or institutions the identities and  
42 locating information of persons, travelers, passengers, or transportation crews  
43 with a similar or common potential exposure to the infectious agent as a reported  
44 case; such exposure may be current or have occurred in the past;
- 45 (e) interviewing or administering questionnaire surveys confidentially to any resident of a  
46 community or any agent, owner, operator, employer, employee, or client of a public or

1 private business or institution, that is either epidemiologically associated with the  
2 outbreak or with the reported communicable disease case or has had a similar exposure as  
3 a reported case;

4 (f) collecting environmental samples of substances or measurements of physical agents that  
5 may be related to the cause of an outbreak or reportable communicable disease;

6 (g) taking photographs related to the purpose of the investigation; If the photographs are  
7 taken in a business, the employer shall have the opportunity to review the photographs  
8 taken or obtained for the purpose of identifying those which contain or might reveal a  
9 trade secret;

10 (h) entering a place of employment for the purpose of conducting investigations of those  
11 processes, conditions, structures, machines, apparatus, devices, equipment, records, and  
12 materials within the place of employment which are relevant, pertinent, and necessary to  
13 the investigation of the outbreak or reportable communicable disease; such investigations  
14 shall be conducted during regular working hours or at other reasonable times and with  
15 such notice as is reasonable under the circumstances.

#### 16 **Regulation 6. Information Sharing**

17 Whenever a local health department or health agency learns of a case of a reportable disease or  
18 an epidemic or communicable disease exposure potentially threatening the public health, it shall  
19 notify the State Department of Health in a timely manner, usually within the timeframe for  
20 reporting in regulation 1.

21 The State Department of Health shall, in turn, notify the appropriate local health department or  
22 agency in a timely manner, usually within the timeframe for reporting in Regulation 1, whenever  
23 it learns of a case of a reportable disease or it learns of an epidemic or communicable disease  
24 exposure potentially threatening the public health.

25 These requirements shall not apply if the State and local health agencies mutually agree not to  
26 share information on reported cases.

27 Sharing of medical information on persons with reportable diseases between authorized  
28 personnel of State and local health departments shall be restricted to information necessary for  
29 the treatment, control, investigation, and prevention of epidemic and communicable diseases  
30 dangerous to the public health.

#### 31 **Regulation 7. Food Handling and Infected Persons**

32 No person, while infected with a disease in a communicable form which can be transmitted by  
33 foods or who is afflicted by a boil, or an infected wound, shall work in a food processing, milk  
34 producing, milk processing or food service setting in any capacity in which there is a likelihood  
35 of such person contaminating food or food contact surfaces with pathogenic organisms or  
36 transmitting diseases to other persons. The employer is responsible for ensuring the absence from  
37 work of an employee with an infectious disease for which there is evidence of transmission to  
38 persons in a food service, food processing, milk producing, or milk processing setting, as  
39 determined by the State Department of Health.

#### 40 **Regulation 8. Reporting of Diseases Among Animals and Waiver Process for Rabies**

##### 41 **Inoculation**

42 A. Every veterinarian, livestock owner, veterinary diagnostic laboratory director, or other  
43 person having the care of, or knowledge of, the existence of animals having or suspected  
44 of having any disease which may endanger the public health such as rabies, anthrax,  
45 encephalitis, bovine spongiform encephalopathy, etc., shall promptly report the facts to  
46 the local health department or health agency or the State Department of Health.

- 1 B. Pursuant to C.R.S. § 25-4-607 (2), a veterinarian licensed in Colorado may issue a written  
2 waiver as provided in this section exempting an animal from a rabies vaccination order if  
3 the veterinarian, in his or her professional opinion, determines the rabies inoculation is  
4 contraindicated due to the animal’s medical condition. The terms “waiver” and  
5 “exemption” as used in this section are interchangeable. A veterinarian may issue a  
6 waiver if:
- 7 1. The animal to be exempted has a medical condition defined as “a disease, illness,  
8 or other pathological state” for which, in the opinion of the exempting  
9 veterinarian, a rabies inoculation is contraindicated;
  - 10 2. A valid veterinary-client-patient relationship, as defined under C.R.S. § 12-64-  
11 103 (15.5), has been established between the veterinarian, owner and animal to be  
12 exempted from rabies inoculation;
  - 13 3. The veterinarian completes and signs the veterinary section of the Exemption  
14 from Rabies Vaccination form provided by the Department;
  - 15 4. The animal owner signs the informed consent section of the Exemption from  
16 Rabies Vaccination form;
  - 17 5. The veterinarian maintains the signed exemption as part of the animal’s medical  
18 record and provides a copy to the owner;
  - 19 6. The exemption issued is limited to the anticipated duration of the animal’s  
20 medical condition that precludes inoculation; and
  - 21 7. The veterinarian provides a copy of the exemption form to the Department, the  
22 local health department or animal control agency when requested.
- 23 C. A waiver may not exceed a period of three years from the date of issuance. If the medical  
24 condition persists beyond a three year period and, in the professional opinion of a  
25 veterinarian licensed in the State of Colorado, the exemption continues to be appropriate,  
26 a new waiver may be issued.
- 27 D. Upon receiving a complaint regarding the validity of a rabies inoculation exemption, the  
28 executive director or his/her designee(s) may review Exemption from Rabies Vaccination  
29 forms and examine the veterinary records pertaining to the medical condition to  
30 determine if the medical condition legitimately contraindicates rabies inoculation. if  
31 appropriate, the executive director or his/her designee(s) may refer the case to the State  
32 Board of Veterinary Medicine.

33 **Regulation 9. Confidentiality**

34 All personal medical records and reports held by the state or local health department in  
35 compliance with these regulations shall be confidential information subject to C.R.S. 25-1-  
36 122(4). Reasonable efforts shall be made by the department to consult with the attending  
37 physician or medical facility caring for the patient prior to any further follow-up by State or local  
38 health departments or health agencies.

39 **Regulation 10. Cleaning and Sterilization of Needles, Instruments, Probes, and**  
40 **Devises Used by Acupuncturists, Tattoo Artists, and Persons Performing Ear or**  
41 **Other Percutaneous Piercing**

42 This regulation is promulgated pursuant to CRS 25-1-107(1)(A) and 12-29.5-111 which state  
43 that the Department has the authority to investigate and control the causes of epidemic and  
44 communicable diseases and that the Department shall promulgate rules relating to the proper  
45 cleaning and sterilization of needles used in the practice of acupuncture and the sanitation of  
46 acupuncture offices. Because bloodborne infections may be transmitted by any contaminated

1 instrument which enters sterile tissue of a patient/client, this regulation is not restricted to  
2 acupuncturists.

3 All parts of the premises of an acupuncture, tattoo, or ear/percutaneous piercing establishment  
4 shall be kept in a clean, sanitary, neat, and orderly condition at all times. All tables, counters, and  
5 chairs used in connection with these procedures shall be constructed of a material which is easily  
6 cleaned and capable of being sanitized with a chemical germicide.

7 Prior to and after each treatment of acupuncture and each application of tattoo or  
8 ear/percutaneous piercing, the applicator shall wash his/her hands at a sink with both hot and  
9 cold running water and with soap having bactericidal qualities.

10 Equipment items shall be defined as any needle, instrument, probe, or device utilized by  
11 acupuncturists, tattoo artists, or persons performing ear/percutaneous piercing that punctures the  
12 skin or enters sterile tissue of any patient/client.

13 The use of sterile, single-use, disposable equipment items is encouraged.

14 Equipment items which have been used to puncture the skin or enter sterile tissue of a  
15 patient/client shall be considered infectious waste. Prior to disposal, such items must be placed in  
16 puncture-resistant containers. Such items should not be recapped, bent, broken, removed from  
17 disposable syringes, or otherwise manipulated by hand after use. Other solid waste, such as  
18 soiled linen, contaminated with blood or other body fluids must be placed in sealed, sturdy,  
19 impervious bags to prevent leakage of the contained items. All infectious waste must be disposed  
20 of in a manner consistent with CRS 25-15-401 et seq. and regulations of the Board of Health  
21 concerning infectious waste disposal.

22 Equipment items must be cleaned and sterilized before such items may be reused. Equipment  
23 items should first be thoroughly cleaned to remove adherent, organic material (e.g. blood and  
24 proteins). Persons involved in cleaning and decontaminating instruments should wear heavy-duty  
25 rubber gloves to prevent hand injuries. Equipment items must then be sterilized by steam  
26 (autoclaving), gas (chemical vapor), or dry heat sterilization. Sterilizers must be installed,  
27 maintained, and operated in conformance with the manufacturer's instructions and specifications.

28 The adequacy of sterilization cycles must be verified by the periodic use of spore-testing devices,  
29 i.e. weekly for most practices, and the operator should keep records which demonstrate the  
30 frequency and results of such testing. Liquid chemical germicides (commonly referred to as  
31 "cold sterilization" solutions), ultrasound, and ultraviolet light cabinets are not acceptable  
32 sterilization methods for metal or heat-stable equipment items. Non-heat-stable equipment items  
33 which enter normally sterile tissue should receive high level disinfection using chemical  
34 germicides that are registered with the U.S. Environmental Protection Agency as "sterilants".

35 The manufacturer's instructions for use of the germicide and the manufacturer's specifications  
36 for compatibility of the equipment item with germicides should be closely followed.

37 Each office, clinic, business, or facility which utilizes equipment items shall be responsible for  
38 insuring that all personnel who use, clean, sterilize, store, dispose, or otherwise handle  
39 equipment items are adequately trained and supervised.

40 All communicable diseases shall be reported by acupuncturists, tattoo artists, and persons  
41 performing ear/percutaneous piercing to the state or local health department in accordance with  
42 Regulations 1 through 4 of these rules.

43 **Regulation 11. Sexually Transmitted Infections**

44 In addition to all manifestations of CHLAMYDIA, syphilis and gonorrhea, the Colorado Board  
45 of Health finds that the following diseases are contagious, are sexually transmissible, are  
46 dangerous to the public health, and pursuant to C.R.S. 25-4-401(1) are determined to be sexually

1 transmitted infections. The Board recognizes that non-sexual transmission may occur for some of  
2 these diseases, and that in individual cases, based on clinical and epidemiologic information, the  
3 attending physician may conclude the patient's disease was not sexually acquired:

4 Chancroid

5 Genital herpes simplex infection

6 Granuloma inguinale

7 Lymphogranuloma venereum

8 Urethritis in males caused by *C. trachomatis*, *U. urealyticum*, *M. genitalium*, *T. vaginalis*,  
9 and Herpes simplex virus

10 Mucopurulent cervicitis in females caused by *C. trachomatis* or *N. gonorrhoeae*

11 Trichomoniasis

12 Pelvic inflammatory disease caused by *C. trachomatis* or *N. gonorrhoeae*

13 Epididymitis caused by *C. trachomatis*, *N. gonorrhoeae*, or *E. coli*

14 Human papillomavirus infection, including genital or anal warts

15 Hepatitis A

16 Hepatitis B

17 Hepatitis C

18 Pediculosis pubis

19 Acute proctitis caused by *C. trachomatis*, *N. gonorrhoeae*, *T. pallidum*, or Herpes simplex  
20 virus

1 **APPENDIX A. HEALTHCARE-ASSOCIATED INFECTIONS**  
2 DEFINITION OF A HEALTHCARE-ASSOCIATED INFECTION: A LOCALIZED OR SYSTEMIC CONDITION  
3 THAT RESULTS FROM AN ADVERSE REACTION TO THE PRESENCE OF AN INFECTIOUS AGENT OR ITS  
4 TOXINS THAT WAS NOT PRESENT OR INCUBATING AT THE TIME OF ADMISSION TO THE HEALTH  
5 FACILITY.

6 HEALTHCARE-ASSOCIATED INFECTIONS INCLUDE:

7 BLOODSTREAM INFECTIONS  
8 BONE AND JOINT INFECTIONS  
9 CARDIOVASCULAR SYSTEM INFECTIONS  
10 CENTRAL NERVOUS SYSTEM INFECTIONS  
11 EYE, EAR, NOSE, THROAT, OR MOUTH INFECTIONS  
12 GASTROINTESTINAL SYSTEM INFECTIONS  
13 LOWER RESPIRATORY TRACT INFECTIONS OTHER THAN PNEUMONIA  
14 PNEUMONIA  
15 REPRODUCTIVE TRACT INFECTIONS  
16 SKIN AND SOFT TISSUE INFECTIONS  
17 SURGICAL SITE INFECTIONS  
18 SYSTEMIC INFECTIONS  
19 URINARY TRACT INFECTIONS

20 HEALTH FACILITY TYPES INCLUDE:

21 AMBULATORY SURGICAL CENTERS  
22 BIRTH CENTERS  
23 CONVALESCENT CENTERS  
24 DIALYSIS TREATMENT CLINICS/END-STAGE RENAL DISEASE FACILITIES  
25 HOSPICES  
26 HOSPITALS (GENERAL, PSYCHIATRIC, REHABILITATION, MATERNITY, AND LONG-TERM  
27 CARE)  
28 LONG-TERM CARE FACILITIES  
29 OUTPATIENT CLINICS (COMMUNITY CLINICS; COMMUNITY CLINICS WITH EMERGENCY  
30 CENTERS; RURAL HEALTH CLINICS; OUTPATIENT REHABILITATION FACILITIES; OUTPATIENT  
31 PHYSICAL THERAPY, OCCUPATIONAL THERAPY OR SPEECH PATHOLOGY SERVICES; AND  
32 PRIVATE PHYSICIAN OFFICES)